Health & Science · November 9, 2026
FDA warns GLP-1 drugs carry potential risk of rare eye condition
FreeGet stories like this compared, every morning at 7.
The Food and Drug Administration (FDA) announced on November 9 that it is requiring all manufacturers of GLP-1 receptor agonist drugs to update their labels with a warning about a rare eye condition. The condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), can cause sudden and painless vision loss that may become permanent. The mandate applies to both diabetes and weight-loss medications in this class, such as Ozempic and Zepbound. The FDA's safety communication follows documentation of NAION cases across all currently marketed GLP-1 products. Health officials advised patients to report sudden visual disturbances immediately and suggested that providers consider discontinuing treatment if the condition is suspected.
Read the original coverage
- STATTrade
FDA warns GLP-1 drugs carry potential risk of rare eye condition
Read at STAT ↗ - MedPage TodayTrade
FDA Slaps New Safety Warning on GLP-1 Drugs
Read at MedPage Today ↗ - The Epoch TimesMainstream
FDA Mandates New Eye Risk Warning on GLP-1 Drugs
Read at The Epoch Times ↗
Reported by multiple outlets
- The FDA is requiring manufacturers of GLP-1 drugs to include a warning about the risk of NAION.
- NAION is a rare but serious eye condition that can lead to permanent vision loss.
- The warning requirement applies to all GLP-1 receptor agonist medications.
- The announcement occurred on November 9.
- NAION typically results from decreased blood flow to the front of the optic nerve.
Reported by only some outlets
- Eli Lilly stated the FDA safety communication does not reference findings specific to its medicines.
- The FDA recommended that healthcare providers consider discontinuing GLP-1 treatment if NAION is suspected unless benefits outweigh the risk.
- Symptoms of NAION are often noticed upon waking and can include color distortion or blurred visual fields.
What the evidence actually shows
The FDA determined that cases of non-arteritic anterior ischemic optic neuropathy (NAION) have been documented across all marketed GLP-1 products, indicating a potential risk of sudden, painless, and potentially permanent vision loss due to reduced blood flow to the optic nerve.
FreeDaily Brief newsletter
Get the 5-minute Daily Brief, with the topics you pick.
The Daily Brief is free
About these outlets
CadNews does not determine absolute truth or endorse political viewpoints. It compares publicly available reporting, identifies shared facts, highlights framing differences, and flags uncertainty.